Supplementary report: surveillance of adverse events following immunisation among children aged <7 years in Australia, 1 January to 30 June 2006
DOI:
https://doi.org/10.33321/cdi.2006.30.42Keywords:
AEFI, adverse events, vaccines, surveillance, immunisation, vaccine safetyAbstract
This report summarises national passive surveillance data collated in the Adverse Drug Reactions Advisory Committee (ADRAC) database at 30 September 2006 for adverse events following immunisation (AEFI) reported for children aged less than 7 years who received vaccines between 1 January and 30 June 2006. It is the first full reporting period for AEFI data following the introduction of a new National Immunisation Program (NIP) schedule, which commenced on 1 November 2005. From that date, varicella vaccine was introduced for children at 18 months of age and inactivated poliovirus vaccines (IPV) replaced oral poliovirus vaccine (OPV) for children at 2, 4 and 6 months and 4 years of age. All children in Australia receive IPV in combined vaccines containing diphtheria-tetanus-acellular pertussis (DTPa) antigens (i.e DTPa-IPV; quadrivalent). In some states and territories, combined vaccines also include hepatitis B (HepB) (i.e. DTPa-IPV-HepB; pentavalent) or both HepB and Haemophilus influenzae type b (Hib) (i.e. DTPa-IPV-HepB-Hib; hexavalent). As a result of these changes, DTPa and DTPa-HepB vaccines are no longer included in the NIP schedule.
Downloads
References
Lawrence G, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, et al. Surveillance of adverse events following immunisation: Australia, 2000–2002. Commun Dis Intell 2003;27:307–323.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2005. Commun Dis Intell 2006;30:319–333.
Lawrence G, Boyd I. Adverse events following immunisation for children aged less than 7 years, 1 January to 30 June 2005. Commun Dis Intell 2005;29:413–416.
Australian Government Department of Health and Ageing. Immunise Australia Program– immunisation programs and initiatives. Available from: http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/programs Accessed December 2006.
Von Kries R, Toschle AM, Strassburger K, Kundi M, Kalies H, Nennsteil U, et al. Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilius influenzae type b): is there a signal? Eur J Pediatr 2005;164:61-69.
Zinka B, Rauch E, B uettner A, Penning R, Rueff F. Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine 2006;24:5779–5780.
Vennemann MMT, Butterfass-Bahloul T, Jorch G, Brinkmann B, Findeisen M, Sauerland C, et al. Sudden infant death syndrome: no increased risk after immunisation. Vaccine 2007;25:336–340. E-pub ahead of print.
Global Advisory Committee on Vaccine Safety. Safety of hexavalent vaccines. Wkly Epidemiol Rec 2005;28:245–246. Available from http://www.who.int/vaccine_safety/reports/June_2005/en/index.html Accessed in December 2006.
National Health and Medical Research Council. The Australian Immunisation Handbook. 8th ed. Canberra: Australian Government Publishing Service; 2003.
Botham SJ, Isaacs D, Henderson-Smart DJ. Incidence of apnoea and bradycardia in preterm infants following DTPw and Hib immunization: a prospective study. J Paediatr Child Health 1997;33:418–421.
Schulzke S, Heininger U, Lucking-Famira M, Fahenstich H. Apnoea and bradycardia in preterm infants following immunisation with pentavalent and hexavalent vaccines. Eur J Pediatr 2005;164:432–435.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2006 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
